about
Immatics NV is a clinical-stage biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-...
Read More
9.70
0.30
(3.19%)
91,649.3
XNAS Volume
XNAS 17 Jul, 2026 12:31 PM (EDT)
Low Financial Strength
Expensive Valuation
Technically Neutral
Momentum Trap
These stocks have weak financials and expensive valuation. Medium technical scores may weaken. Investors should exercise caution
View Similar
Embed DVM
Immatics N.V Live Price Chart
Switch to TradingView
Loading Fundamental data..
Loading data..